These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 36879459)

  • 1. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
    Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
    Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
    Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
    [No Abstract]   [Full Text] [Related]  

  • 4. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
    Hua J; Zhang J; Zhang X; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu C; Chen S; Tang X; Wu D; Qiu H
    Bone Marrow Transplant; 2021 May; 56(5):1056-1064. PubMed ID: 33235353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion.
    Liang Z; Xu H; Zhou X; Yang J; Tu S; He Y; Zhou L; Li Y
    Hum Cell; 2023 Sep; 36(5):1716-1728. PubMed ID: 37418233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang T; Gao L; Hu X; Liu B; Chen J; Zhang W; Wang J; Yu X; Feng D; Chang AE; Max W; Tang G; Li Q; Yang J
    J Immunother; 2019 Apr; 42(3):81-88. PubMed ID: 30829725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
    [No Abstract]   [Full Text] [Related]  

  • 12. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.
    Li Y; Li Y; Zhang M; Zhao H; Zhu M; Huang H; Hu Y
    Eur J Haematol; 2024 Jan; 112(1):94-101. PubMed ID: 37477866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
    Song Y; Liu Z; Wang Q; Gao K; Wu T
    Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.
    Martínez-Romera I; Galán-Gómez V; González-Martínez B; Guerra García P; San Román Pacheco S; Corral Sánchez D; Mozo Del Castillo Y; Bueno Sánchez D; Sisinni L; González Guerrero A; Castellano Dámaso S; Sánchez Zapardiel E; Ruz Caracuel B; Balas Pérez A; Pérez-Martínez A
    Front Immunol; 2022; 13():960412. PubMed ID: 36003375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
    Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.